Scarica l'app Stockscreener
1.125
2.17%
-0.025
Dopo l'orario di chiusura:
1.13
0.005
+0.44%
Precedente Chiudi:
$1.15
Aprire:
$1.16
Volume 24 ore:
61,713
Relative Volume:
0.32
Capitalizzazione di mercato:
$30.74M
Reddito:
-
Utile/perdita netta:
$-37.38M
Rapporto P/E:
-0.9073
EPS:
-1.24
Flusso di cassa netto:
$-35.50M
1 W Prestazione:
+0.45%
1M Prestazione:
+2.27%
6M Prestazione:
+1.35%
1 anno Prestazione:
+2.27%
Intervallo 1D:
$1.11
$1.165
Intervallo di 1 settimana:
$1.09
$1.17
Portata 52W:
$0.975
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Confronta ANTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.125 | 30.61M | 0 | -37.38M | -35.50M | -1.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Mountain Crest Acquisition Corp. II/Better Therapeutics, Inc. Class Action – Important Settlement Information - Business Wire
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - The Malaysian Reserve
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - PR Newswire
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-Q Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - Yahoo Finance
Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - simplywall.st
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - Business Wire
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - Yahoo Finance
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Yahoo Finance
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire
New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewswire
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - GlobeNewswire
Cognition Therapeutics Reports Over 50% Enrollment in Phase 2 START Study for Alzheimer's Treatment - Nasdaq
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - BioSpace
Allarity Therapeutics Announces Dosing of Second Patient in - GlobeNewswire
Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001 - Ophthalmology Times
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
Cidara Therapeutics Announces Positive Topline Results from - GlobeNewswire
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
An 2 Therapeutics Inc Azioni (ANTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Easom Eric | Chief Executive Officer |
Jun 02 '25 |
Buy |
1.07 |
10,000 |
10,665 |
256,380 |
| Leonard Braden Michael | 10% Owner |
May 28 '25 |
Sale |
1.16 |
2,100,000 |
2,436,000 |
3,649,432 |
| Leonard Braden Michael | 10% Owner |
May 30 '25 |
Sale |
1.01 |
432,000 |
436,477 |
3,217,432 |
| FitzPatrick Margaret M | Director |
May 28 '25 |
Buy |
1.18 |
8,610 |
10,133 |
8,610 |
| Day Lucy | Chief Financial Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
32,670 |
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):